Latest news about Bharat Parenterals
Bharat Parenterals: U.S. FDA Issues 5 VAI Observations Following Surprise Inspection at InnoXel Lifesciences
Bharat Parenterals
1,240.10
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M+0.72%
6M+11.43%
1Y+16.16%
5Y+213.83%
More news about Bharat Parenterals
30Jan 26
Bharat Parenterals Q3FY26 Results: Revenue Declines 38.5% YoY to ₹41.41 Crore, Order Book at ₹303 Crore
Bharat Parenterals delivered mixed Q3FY26 results with standalone revenue declining 38.5% YoY to ₹41.41 crore due to timing delays in institutional orders. The company disclosed a strong order book of ₹303 crore for future execution and expects recovery in Q4FY26 with revenue guidance of ₹50-55 crore.
01Jan 26
Bharat Parenterals Limited Appoints Keval Sanjaykumar Shah as Vice President - Operations
Bharat Parenterals Limited has appointed Mr. Keval Sanjaykumar Shah as Vice President - Operations effective January 01, 2026, under SEBI Regulation 30 compliance. Mr. Shah brings over 10 years of experience in supply chain, project management, and business development, holding an MBA from IMT Ghaziabad. The company describes him as a results-driven professional whose expertise in operations management and strategic decision-making will support the organization's growth phase.
17Nov 25
Bharat Parenterals Q2 FY26 Revenue Dips 35% Amid Production Upgrades, Maintains Growth Outlook
Bharat Parenterals Limited experienced a 35.35% year-over-year revenue drop in Q2 FY26, with standalone revenue falling to ₹41.70 crore from ₹64.50 crore in Q2 FY25. The decline is attributed to planned production upgrades and deferred export dispatches. Despite this, the company maintains its FY26 guidance, projecting 12-14% revenue growth and 15-17% EBITDA margins. Its subsidiary, Innoxel, secured US FDA approval and signed 7 new partnerships worth $1.85 million, potentially boosting future performance.
28Jul 25
Bharat Parenterals Targets ₹350 Crore Revenue by FY26, Reports Strong Q1 Performance
Bharat Parenterals Limited (BPL) aims to achieve over ₹350 crore in consolidated revenue by FY26. Q1 saw strong performance with consolidated revenue up 25.4% to ₹116.00 crore. Growth strategies include expanding Innoxel's CDMO operations, scaling Varenyam Healthcare to ₹100 crore by FY28, and developing Varenyam Biolifesciences for regulated emerging markets. BPL projects 12-14% revenue growth and 15-17% EBITDA margin for standalone operations, with additional revenue targets for subsidiaries.
28Jul 25
Bharat Parenterals Announces Board Changes and Strong Q1 Performance
Bharat Parenterals Limited (BPL) reported Q1 consolidated revenue of ₹116.00 crores, up 25.40% year-on-year, with EBITDA at ₹13.78 crores. The company announced board changes including the appointment of Mr. Alkesh Shah as Non-Executive Director and re-appointment of Mr. Mukeshbhai Patel as Independent Director. BPL's subsidiaries show progress, with Innoxel Lifesciences developing over 20 differentiated molecules and Varenyam Healthcare present in 7,500+ hospitals. The company projects 12-14% standalone revenue growth for the current fiscal year.
28Jul 25
Bharat Parenterals Reports Q1FY26 Results, Announces Board Changes and AGM Date
Bharat Parenterals Limited (BPL) reported its Q1 FY26 results. Standalone revenue increased by 2.50% to ₹94.37 crore, while consolidated revenue grew 25.40% to ₹116.00 crore. The company narrowed its consolidated net loss to ₹0.87 crore. BPL projects standalone revenue growth of 12-14% for FY26 with an EBITDA margin of 15-17%. Board changes include Mr. Sanjay Shah's resignation and Mr. Alkesh Jayantilal Shah's appointment as Additional Non-Executive Non-Independent Director. The 32nd AGM is scheduled for September 26, 2025.
12May 25
Bharat Parenterals Q4 FY23: EBITDA Surges Despite Widening Net Loss
Bharat Parenterals Ltd. (BPL) released Q4 FY23 results showing strong operational growth but increased net loss. Revenue rose 47.49% YoY to ₹100.00 crore, EBITDA doubled to ₹22.00 crore with margin improving to 2.14%. However, net loss widened to ₹4.70 crore from ₹0.30 crore in Q4 FY22.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Lupin
Mankind Pharma
Zydus Life Science
Aurobindo Pharma
Laurus Labs
1,824.80
(-1.13%)
6,796.00
(+2.29%)
4,295.80
(-1.96%)
1,327.60
(+2.73%)
1,265.30
(-0.37%)
2,215.60
(-1.33%)
2,407.60
(+1.21%)
939.25
(+0.92%)
1,497.50
(+0.62%)
1,280.50
(+0.99%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
